REG - Venture Life Group - Notice of Results

Venture LifeAnnouncement

01/04/2020 15:15

RNS Number : 4554I
  
Venture Life Group PLC
  
01 April 2020
  
 

1 April 2020
 
Venture Life Group plc
("Venture Life" or the "Company")
Notice of Results
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market, today announces that it will announce its preliminary results for the year ended 31 December 2019 on Thursday 9 April 2020.
For further information please contact: 



Venture Life Group PLC


+44 (0) 1344 578 004




Jerry Randall, Chief Executive Officer








Andrew Waters, Chief Financial Officer
 








Cenkos Securities plc (Nominated Adviser and broker)


+44 (0) 207 397 8900




 
Stephen Keys / Cameron MacRitchie (Corporate Finance)
Russell Kerr / Michael Johnson (Sales)








Alma PR


venturelife@almapr.com or 
+44 (0) 203 405 0208




Helena Bogle/Hilary Buchanan/Kieran Breheny







 
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on acquiring, developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy and the Netherlands, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, , medical devices for dermatology, oral care, women's intimate healthcare and proctology, and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and the Netherlands these are supplied direct by the company, elsewhere they are supplied by the Group's international distribution partners. 
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the OTC consumer products sector, primarily in respect of medical devices.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
NORZFLFBBZLBBBE